| scholarly article | Q13442814 |
| P2093 | author name string | Jeong Eun Song | |
| Byung Seok Kim | |||
| Chang Hyeong Lee | |||
| Han Na Choi | |||
| Hyeon Chul Lee | |||
| Hyeong Ho Jo | |||
| P2860 | cites work | Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response | Q58097652 |
| Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety | Q58235847 | ||
| Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B | Q83395636 | ||
| Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients | Q84280056 | ||
| Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy | Q84901434 | ||
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments | Q30830513 | ||
| Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization | Q30853725 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? | Q34296276 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. | Q34600796 | ||
| Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature | Q35139832 | ||
| State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases | Q35388339 | ||
| KASL Clinical Practice Guidelines: Management of chronic hepatitis B. | Q36153966 | ||
| Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. | Q36740264 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | Q37278241 | ||
| Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response | Q37359386 | ||
| Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy | Q42222328 | ||
| Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. | Q42259021 | ||
| Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. | Q43102284 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. | Q43286736 | ||
| Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. | Q43755030 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years | Q43914060 | ||
| Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. | Q44079403 | ||
| Statements from the Taormina expert meeting on occult hepatitis B virus infection | Q45391959 | ||
| Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice | Q46115516 | ||
| Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. | Q46252667 | ||
| Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine | Q46552174 | ||
| The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. | Q46572233 | ||
| Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. | Q46827681 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | virology | Q7215 |
| entecavir | Q418586 | ||
| chronic hepatitis | Q62019625 | ||
| chronic hepatitis B | Q55779876 | ||
| P304 | page(s) | 24-31 | |
| P577 | publication date | 2015-03-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir | |
| P478 | volume | 21 |
| Q40739807 | 5-year efficacy of entecavir in Indian patients with chronic hepatitis B. |
| Q64085332 | Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis |
| Q47654528 | Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B. |
| Q55364394 | Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. |
| Q92933244 | Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice |
| Q40409098 | Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. |
| Q39443390 | Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world |
Search more.